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Summary
Biosynthesis of the molybdenum cofactor (MoCo) can
be divided into (1) the formation of a precursor and (2)
the latter’s subsequent conversion, by molybdopterin
synthase, into the organic moiety of MoCo. These two
steps are reflected by the complementation groups A and
B and the two formally distinguished types of MoCo
deficiency that have an identical phenotype. Both types
of MoCo deficiency result in a pleiotropic loss of all
molybdoenzyme activities and cause severe neurological
damage. MOCS1 is defective in patients with group A
deficiency and has been shown to encode two enzymes
for early synthesis via a bicistronic transcript with two
consecutive open reading frames (ORFs). MOCS2 en-
codes the small and large subunits of molybdopterin
synthase via a single transcript with two overlapping
reading frames. This gene was mapped to 5q and com-
prises seven exons. The coding sequence and all splice
site–junction sequences were screened for mutations, in
MoCo-deficient patients in whom a previous search for
MOCS1 mutations had been negative. In seven of the
eight patients whom we investigated, we identified
MOCS2 mutations that, by their nature, are most likely
responsible for the deficiency. Three different frameshift
mutations were observed, with one of them found on 7
of 14 identified alleles. Furthermore, a start-codon mu-
tation and a missense mutation of a highly conserved
amino acid residue were found. The locations of the
mutations confirm the functional role of both ORFs.
One of the patients with identified MOCS2 mutations
had been classified as type B, in complementation stud-
ies. These findings support the hypothetical mechanism,
for both forms of MoCo deficiency, that formerly had
been established by cell-culture experiments.
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Introduction
Molybdenum cofactor (MoCo) (MIM 252150 [type A]
and MIM 252160 [type B]) deficiency is a rare auto-
somal recessive disease with ∼70 known cases found
worldwide (C. Dorche and J. Reiss, unpublished data).
This disorder leads to the pleiotropic loss of all molybdo-
enzyme activities (Duran et al. 1978; Johnson et al.
1980). The absence of an active sulfite oxidase results
in severe neurological damage and early childhood death
(Johnson and Wadman 1995). The most prominent clin-
ical features are neonatal seizures unresponsive to any
therapy, including massive molybdenum intake (Duran
et al. 1978; Johnson et al. 1980). Molybdenum is co-
ordinated in molybdoenzymes either in the form of a
MoCo or as a component of an iron-molybdenum co-
factor (Rajagopalan and Johnson 1992). The iron-mo-
lybdenum cofactor is found exclusively in the eubacterial
nitrogenase (Ludden et al. 1993); all other molybdoen-
zymes contain the universal MoCo (Rajagopalan and
Johnson 1992). This cofactor consists of the metal ion
and a small organic moiety called “molybdopterin”
(MPT) (Johnson and Rajagopalan 1982; Boyington et
al. 1997). MPT is identical in all studied organisms,
although some eubacteria form a dinucleotide from
MoCo and either GTP or CTP (Rajagopalan and John-
son 1992), and some archae- or eubacteria use tungsten
instead of the molybdenum ion (Huber et al. 1994; Chan
et al. 1995). Free MPT is not stable, and all organisms
share a conserved pathway for its biosynthesis (Mendel
1997). Complementation studies with cell cultures de-
rived from MoCo-deficient patients suggest that group
A cells are defective in the formation of precursor Z
from GTP and that type B cells are defective in MPT
synthase that normally converts the precursor to MPT
(Johnson et al. 1989).
Elsewhere we have described the isolation of MOCS1,
which encodes the two enzymes necessary for precursor
Z formation in two consecutive open reading frames
(ORFs) on a single transcript (Reiss et al. 1998b). Mu-
tations were detected in both of these frames and to-
gether account for ∼70% of the cases of MoCo defi-
ciency (Reiss et al. 1998a). The remaining patients most
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Figure 1 Schematic illustration of the MPT biosynthesis path-
way. The participating enzymes are at the top; the corresponding genes
and complementation groups are at the bottom.
likely belong to complementation group B, with a defect
in the heterodimeric MPT synthase (fig. 1). The small
and large subunits of this converting factor (Johnson et
al. 1989) again are encoded in a single and uniform
transcript, but, in contrast to the MOCS1 transcript, the
two corresponding ORFs overlap by 77 nucleotides
(Stallmeyer et al. 1999 [in this issue]). We here describe
both the genomic structure of the MPT-synthase gene,
called “MOCS2” (MoCo synthesis step 2), and the iden-
tification of mutations in MoCo-deficient patients neg-
ative for MOCS1 mutations.
Subjects and Methods
Subjects
MoCo deficiency comes to clinical attention through
neonatal seizures unresponsive to any therapy, opistho-
tonos, and facial dysmorphism (Johnson and Wadman
1995). Elevated sulfite levels can be found in fresh urine
samples, by means of simple test strips originally pro-
duced for control of wine or fruit juices (Merckoquant
1.10013; Merck). Other biochemical findings include
hypouricemia, which is not observed in the otherwise
similar phenotype of isolated sulfite oxidase deficiency
(Irreverre et al. 1967), as well as abnormal sulfur and
purine metabolites (Duran et al. 1978; Johnson et al.
1980). In all cases the sulfite oxidase deficiency has been
tested and found to be absent in fibroblast cultures,
which were also used for standard procedures of DNA
isolation. In addition, EDTA samples of peripheral blood
were prepared according to “salting out” procedures
(Miller et al. 1988). All patients described in the present
study had been previously screened for mutations in the
MOCS1 gene (Reiss et al. 1998a). For one patient (Boles
et al. 1993), the complementation group was known
(type B). All investigations were been approved by the
ethics committee of the medical faculty of the University
of Go¨ttingen.
Complementation Studies
After verification of their growth potential, fibroblast
cell lines were mixed in a 1:1 ratio, grown for 7 d,
trypsinized, replated, and grown for another 10 d. After
cell harvest, complementation was tested by the mea-
surement of sulfite oxidase activity in a crude extract of
sonicated cells, as described by Garrett and Rajagopalan
(1994).
Molecular Genetic Analysis
Isolation of the MOCS2 cDNA (GenBank) is de-
scribed in the accompanying paper (Stallmeyer et al.
1999). Unknown genomic sequences were amplified by
means of a Genome walker kit (Clontech), with Ad-
vantage genomic polymerase mix (Clontech). Essen-
tially, genomic DNA was digested with various restric-
tion endonucleases prior to the ligation of universal
DNA adaptors. Subsequent DNA amplification was
done with a combination of one adaptor-specific and
one gene-specific primer. Oligonucleotides used for PCR
amplification of individual exons plus their flanking
splice site–junction sequences are listed in table 1. PCR
was done in an Eppendorf master cycler (30 cycles of
92C for 1 min, 50C for 45 s, and 63C for 3 min),
with TaqPCR master mix (Qiagen) including “Q-solu-
tion.” When nested PCR was done, the first round con-
sisted of 15 cycles followed by 30 cycles after a 1:50
dilution of the template. Amplification products were
column purified (Qiagen) and directly sequenced in cy-
cles, on both strands, with the oligonucleotides used for
PCR (table 1) and with Big Dye Terminator Mix (ABI).
The sequence reaction products were purified by ethanol
precipitation and were analyzed by electrophoresis on a
377A sequencing machine (ABI). A genomic PAC (plas-
mid artificial chromosome) clone was used for FISH on
metaphase chromosomes after random-primed digoxi-
genin labeling. For radiation hybrid mapping, the Stan-
ford G3 panel was purchased (Research Genetics) and
was tested with primers F5 and R9 (table 1) in a PCR
(30 cycles of 94C for 1 min, 55C for 1 min, and 72C
for 1 min), with Taq Polymerase (Promega).
Results
Analysis of genomic DNA revealed six introns within
the MOCS2 gene. The genomic structure is illustrated
in figure 2. The sizes of the individual exons and their
splice site–junction sequences are listed in table 2. The
small subunit of MPT synthase (i.e., MOCS2A) is en-
coded by exons 1–3, and the large subunit (i.e.,
MOCS2B) is encoded by exons 3–7. The overlap of these
two ORFs (by 77 nucleotides) is limited to exon 3. FISH
analysis of digoxigenin-labeled genomic PAC clones on
metaphase chromosomes indicated a genomic map po-
sition on the long arm of chromosome 5, close to the
centromere (data not shown). PCR screening of a ra-
diation-induced cell-hybrid panel resulted in a human-
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Figure 2 Genomic structure of the MOCS2 gene, and location
of described mutations. Exons are represented by open boxes and are
identified by the numbers within the boxes. Between the exons the
intron size (in kb) is given, if known. Exons and introns are not drawn
to scale. The labeled horizontal black bars at the top indicate the
locations of the mutations described in the text. Start and stop codon
of the two ORFs are illustrated by the upward-pointing arrows below.
Table 1








1 F27 (TGA GCC CGC GCC TGC GCC TTT) R19 (TAG TGG GGA GGT CCG ACT GAC CA) 183
2 F17 (CAG TCA GAA AAC GAG TAT GAG TTG) R17 (AAG TGT TAC TCATAT GCA TTC TAC) 212
3 F18 (GAG GTC TAT CAT AGC GTT GAT AC) R18 (TCA TCT GTA TGA TCC TTC CCC) 249
4 F23 (CCC TAG GAC TTC TGT TAA GGT TTG) R20 (ACA CTG AAC ATG GAA AGC ACA TGC) 245
5A F16 (TTA GAA GAA TTG GTA TGC TGC TTG) R4 (TAA CAG CCA TCC CTA TTG TCC TCC) 437
5B F21 (CGT GCT ATT TCT TTT GTA GGG) R21 (TCA GAG TTA GTA CAA AGA TGG) 316
6 F5 (CAC GTA GAT TCA GAG ATG ATG GTG) R9 (CAG GTC CAC ATG CTA AAA TGT G) 213
7A F22 (TGC CCA TGA TGT CTC TCG TCA TGA R22 (CTT CAG TAA ACT ATC CTG ATG TGG) 312
7B F19 (GGA GCC ATT GAA ATA GAT GTG) R3 (TAA TAG TTT AAC AAA GTT AAG) 224
a Exons 5 and 7 were amplified first with the “A” primers and then with the nested “B” primers.
specific signal and placed the MOCS2 locus in the region
5p11-5q11, closely linked to expressed sequence tag
(EST) marker SHGC-36388 and in the vicinity of the
polymorphic markers D5S660 and D5S623. This con-
firmed a chromosomal position at 5q11, for MOCS2.
Individual exons and their flanking sequences were
amplified from the genomic DNA of patients in whom
previous screening for MOCS1 mutations had produced
a negative result (Reiss et al. 1998a). In seven of the
eight patients investigated, MOCS2 mutations could be
identified (table 3). Six of these seven patients are ho-
mozygous for a MOCS2 mutation, and one is compound
heterozygous for two different mutations affecting the
same ORF. The most frequent mutation is a 2-bp de-
letion (726del2) removing the last nine amino acids of
MOCS2B, of which two are conserved (Stallmeyer et al.
1999). This mutation was found homozygous in three
different patients and in the compound-heterozygous pa-
tient. It therefore accounts for 50% (7 of 14) of the
identified alleles. Two other frameshift mutations were
detected as homozygous in one patient each: 252insC
affects both MOCS2A and MOCS2B and removes con-
served motifs from both proteins; 533del4 truncates
MOCS2B, and the affected amino acid residues include
the conserved motif that is also destroyed by 726del2.
Because the start codon represents the only methio-
nine codon within MOCS2A, the point mutation M1I
(ATGrATA) found to be homozygous in one affected
patient is expected to result in a complete loss of
MOCS2A. In vitro translation experiments with a mu-
tated MOCS2A start codon confirmed this assumption
(Stallmeyer et al. 1999). In one patient heterozygous for
the frameshift mutation 726del2, a point mutation af-
fecting the first nucleotide of exon 7 was identified, re-
sulting in the missense mutation E168K (GAArAAA).
Family analysis revealed that E168K is on the maternal
chromosome and that 726del2 is the paternal allele.
E168 is one of the few extremely conserved residues in
MOCS2B (Stallmeyer et al. 1999), and the amino acid
substitution E168K is most likely sufficient for the im-
pairment of the protein’s enzymatic activity. The sub-
stituted G, however, contributes to the consensus value
of a splice site (Krawczak et al. 1992), and an additional
effect on splicing efficiency cannot be excluded.
Neither M1I (DMOCS2A) nor E168K was found in
50 healthy control individuals. We could not investigate
the parents of the patients homozygous for one of the
aforementioned mutations. However, no quantitative in-
dication of hemizygosity by gross gene deletion was ob-
served in any of the PCR amplifications. Furthermore,
anamneses of families with MoCo-deficient patients
have revealed a high percentage of consanguineous par-
ents, which is known for the two homozygous patients
clinically described elsewhere: Boles et al. (1993) re-
ported on the patient with the start-codon mutation
M1I, and Bonioli et al. (1996) reported on the patient
with deletion 533del4. Fibroblasts from four of seven
patients with MOCS2 mutations and from the only re-
maining patient of our cohort who did not haveMOCS1
or MOCS2 mutations were tested for complementation
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Table 2
Sizes of MOCS2 Exons and Splice-Junction Sequences
Exon Nucleotides
Length
(bp) Amino Acids 3′ Junctiona 5′ Junctiona
1 1–18 118 1–6 CAGgtaagggtggcg
2 19–140 122 7–47 ctttactttcagGTT TGGgtagttaaaaat
3 141–285 145 48–88, 1–33 tttcccctttagATT TAGgtatgtgagatt
4 286–413 128 34–75 tattatttctagGAA TAGgtgagttgtaat
5 414–564 151 76–126 tcatttttaaagGGA TGGgtatgatttcct
6 565–688 124 127–167 atcttgttaaagCTT AAGgtaagttaagaa
7 689–1264 576 168–188 tttgttttttagGAA
a Reference is to the corresponding intron.
Table 3
Genotypes of Patients with Identified MOCS2 Mutations
Genotype Exon Ethnic Origin Affected Proteins
M1I /M1I 1 Coptic Egyptian MOCS2A/MOCS2A
252insC/252insC 3 Portuguese MOCS2A/MOCS2A,
MOCS2B/MOCS2B
533del4/533del4 5 Italian MOCS2B/MOCS2B
E168K /726del2 7 German MOCS2B/MOCS2B
726del2/726del2 7 French MOCS2B/MOCS2B
726del2/726del2 7 Portuguese MOCS2B/MOCS2B
726del2/726del2 7 English MOCS2B/MOCS2B
among each other and after cocultivation with fibro-
blasts from patients with MOCS1A and MOCS1B mu-
tations (Reiss et al. 1998a). This confirmed that they all
belong to complementation group B. Representative re-
sults are listed in table 4 and illustrate the relationship
between identified mutations and the two complemen-
tation groups.
Discussion
Several assumptions and hypotheses put forward pre-
viously are confirmed by the present study: the molecular
basis for the observation of two complementation
groups in MoCo deficiency (Johnson et al. 1989) is two
distinct MOCS genes on different chromosomes, one en-
coding enzymatic activities leading to the formation of
precursor Z (Reiss et al. 1998a, 1998b) and one encod-
ing for the small and large subunits of the heterodimeric
MPT synthase, which converts the precursor to MPT.
Because both of the corresponding transcripts encode
two proteins, future experiments might reveal more than
two complementation groups after cell fusion. This the-
oretical possibility, however, is unlikely if either colinear
transcription or microcompartmentalization of either
MOCS1A and MOCS1B or MOCS2A and MOCS2B,
respectively, are indispensable for MoCo synthesis.
Fibroblasts of the only patient without identified mu-
tations (described by Desjaques et al. 1985) are com-
plemented by fibroblasts of complementation group A.
This rules out an unidentified defect in theMOCS1 gene.
No complementation is observed after cocultivation
with group B cells. The patient therefore formally be-
longs to group B, which leaves the possibility of an as
yet unidentified disease-causing mutation in noncoding
regions of the MOCS2 gene—for example, a promoter
mutation or the activation of a cryptic splice site (Kraw-
czak et al. 1992). Another possibility is the existence of
a third MOCS gene with disease-causing potential. Be-
cause of the observed complementation behavior, the
putative gene product should either interact with MPT
synthase or be involved in the insertion of molybdenum
into the MPT (Johnson et al. 1989; Mendel 1997).
The identification of alterations—which, by their na-
ture and position, can clearly be assumed to be disease
causing—in both ORFs of the bicistronic MOCS2 gene
confirms not only that both proteins encoded by these
overlapping ORFs are expressed but, furthermore, that
the expression of both ORFs is indispensable for a nor-
mal phenotype. It is counterintuitive that the twofold
observation of an unusual architecture such as a bicis-
tronic eukaryotic transcript in both MOCS1 (Reiss et al.
1998b) and MOCS2 (present study) should be coinci-
dental. The fusion of genes for the sake of synchronized
expression and microcompartmentalization appears to
be a frequent event in eukaryotic evolution (Amy et al.
1992; Davidson et al. 1993), and the transcription of
bothMOCS1 andMOCS2 seems to proceed by the usual
means. In both cases, however, the fusion of the two
encoded proteins into one multicatalytic enzyme has not
happened. Because the mode of the unusual translation
of a second ORF in case of MOCS1 with two consec-
utive ORFs seems to be a reinitiation (Reiss et al. 1998b)
but, in the case of MOCS2 with two overlapping ORFs,
leaky scanning (Stallmeyer et al. 1999), the mode of
expression of the second ORF seems not to be correlated
with the phenomenon of multiple bicistronic transcripts
in one biochemical pathway.
Another common feature of MOCS1 and MOCS2
might be important in this context. Both proteins en-
coded by the first ORF—MOCS1A and MOCS2A—end
with a highly conserved and identical motif: glycine-
glycine-stop. Again, a coincidence is unlikely, and the
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Table 4
Enzymatic Activity of Cultured and Cocultured Fibroblasts





Wild type 1 3.1
Wild type 2 7.7
MOCS1A (722delT/722delT)  MOCS1A
(G324E/G324E) ND
MOCS1A (722delT/722delT)  MOCS1B
(1523del2/1523del2) ND
MOCS1A (722delT/722delT)  MOCS2B
(756del2/756del2) 4.1
MOCS1B (1313insG/T182P)  MOCS2B
(756del2/756del2) 3.9
a ND  not detectable.
importance of these extremely conserved residues is fur-
ther emphasized by the observation of a corresponding
MOCS1 mutation of the penultimate glycine codon
(G384S) in a MoCo-deficient patient (Reiss et al. 1998a).
The importance of a C-terminal glycine-glycine motif
has already been highlighted, by Pickart et al. (1994),
for ubiquitin, in which the terminal glycine seems to be
necessary for a transthiolation. Taylor et al. (1998) have
pointed out that both thiS and moaD, the bacterial ho-
mologue of MOCS2A, carry two C-terminal glycine res-
idues probably also involved in a transthiolation. In
summary, these data suggest that the evolutionarily fa-
vored fusion of MoCo biosynthesis enzymes is stuck
twice on the level of a fused transcript, because of the
necessity of a free C-terminal motif for the enzymatic
activities of both MOCS1A and MOCS2A.
All described MOCS2 mutations affect one or more
highly conserved motifs. As observed in the MOCS1-
mutation screening (Reiss et al. 1998a), no missense mu-
tation of a less conserved residue was identified. This
parallels the absence of mild or partial forms of MoCo
deficiency and supports the hypothesis of a qualitative
“yes or no” mechanism—rather than quantitative ki-
netics—for MoCo function; that is, this function is either
completely abolished or sufficient for a normal pheno-
type. This theory may provide hope for a successful gene
therapy in this hitherto incurable disease (Reiss et al.
19981998a; Wolff 1997). Precursor-producing cells
seem to be capable of feeding their precursor-deficient
neighbor cells, but no such effect can be expected for
excretion and uptake of MPT synthase (Johnson et al.
1989). Therefore, MOCS2 supplementation, in com-
parison with MOCS1 delivery, might require a larger
number of cured cells, for a successful gene therapy.
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